PTS-101

PTS-101 is a preclinical-stage small molecule drug candidate developed by Metis Pharmaceuticals, specifically designed for the animal health market. It targets obesity, overweight conditions, and metabolic dysfunction in pets. As part of Metis Pharmaceuticals' specialized pipeline for companion animals, PTS-101 aims to address the growing prevalence of metabolic disorders in the veterinary sector. While the specific mechanism of action and molecular target remain proprietary and undisclosed, the candidate represents the company's expansion of its small molecule discovery capabilities into veterinary therapeutics.